Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
21
IPSC Quote, Financials, Valuation and Earnings
Last price:
$0.57
Seasonality move
:
-30.11%
Day range:
$0.51 - $0.53
52-week range:
$0.34 - $1.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.40x
P/B ratio:
0.26x
Volume:
463.2K
Avg. volume:
1.3M
1-year change:
-63.24%
Market cap:
$45.9M
Revenue:
$6.6M
EPS (TTM):
-$0.31
Analysts' Opinion
-
Consensus RatingCentury Therapeutics, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.00, Century Therapeutics, Inc. has an estimated upside of 470.78% from its current price of $0.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.53.
Fair Value
-
According to the consensus of 2 analysts, Century Therapeutics, Inc. has 470.78% upside to fair value with a price target of $3.00 per share.
IPSC vs. S&P 500
-
Over the past 5 trading days, Century Therapeutics, Inc. has underperformed the S&P 500 by -3.91% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Century Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Century Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Century Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Century Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Century Therapeutics, Inc. reported earnings per share of -$0.40.
Enterprise value:
-41.9M
EV / Invested capital:
-0.19x
Price / LTM sales:
0.40x
EV / EBIT:
--
EV / Revenue:
-0.37x
PEG ratio (5yr expected):
-0.49x
EV / Free cash flow:
0.37x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$100.5M
Return On Assets:
-8.34%
Net Income Margin (TTM):
-23.36%
Return On Equity:
-13.46%
Return On Invested Capital:
-10.67%
Operating Margin:
67.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.5M | $2.7M | $113.3M | $791K | -- | |
| Gross Profit | -$7.3M | -$10.9M | $100.5M | -$2.5M | -$3.1M | |
| Operating Income | -$127.9M | -$132.6M | -$22.7M | -$35.1M | -$29.1M | |
| EBITDA | -$118.1M | -$119M | -$9.8M | -$31.8M | -$26M | |
| Diluted EPS | -$2.19 | -$1.86 | -$0.31 | -$0.37 | -$0.40 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $300.4M | $361.6M | $173.7M | $206M | $137.7M | |
| Total Assets | $469.7M | $511.8M | $397.6M | $388.6M | $244.7M | |
| Current Liabilities | $19.9M | $26.9M | $20.4M | $19.8M | $22M | |
| Total Liabilities | $46.7M | $181.5M | $178.3M | $192.9M | $68.4M | |
| Total Equity | $423M | $330.2M | $219.2M | $195.7M | $176.3M | |
| Total Debt | $24.6M | $46.8M | $45.5M | $50.8M | $41.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$85.4M | -$112.1M | -$112M | -$28.3M | -$25.6M | |
| Cash From Investing | $38.3M | $35.5M | $115.7M | $39.2M | $24.7M | |
| Cash From Financing | -$9.3M | $74.8M | -$482K | $273K | -- | |
| Free Cash Flow | -$104.4M | -$113.1M | -$113.2M | -$27.5M | -$25.8M | |
IPSC
Sector
Market Cap
$45.9M
$28.5M
Price % of 52-Week High
30.21%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-34.96%
-1.33%
1-Year Price Total Return
-63.25%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.53
200-day SMA
Sell
Level
$0.55
Bollinger Bands (100)
Sell
Level
0.5 - 0.58
Chaikin Money Flow
Buy
Level
3.8M
20-day SMA
Buy
Level
$0.52
Relative Strength Index (RSI14)
Sell
Level
48.72
ADX Line
Buy
Level
13.07
Williams %R
Neutral
Level
-25.7377
50-day SMA
Sell
Level
$0.54
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
8.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.8472)
Sell
CA Score
(Annual)
Level (-2.2241)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.0821)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Stock Forecast FAQ
In the current month, IPSC has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IPSC average analyst price target in the past 3 months is $3.00.
-
Where Will Century Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Century Therapeutics, Inc. share price will rise to $3.00 per share over the next 12 months.
-
What Do Analysts Say About Century Therapeutics, Inc.?
Analysts are divided on their view about Century Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Century Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Century Therapeutics, Inc.'s Price Target?
The price target for Century Therapeutics, Inc. over the next 1-year time period is forecast to be $3.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IPSC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Century Therapeutics, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of IPSC?
You can purchase shares of Century Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Century Therapeutics, Inc. shares.
-
What Is The Century Therapeutics, Inc. Share Price Today?
Century Therapeutics, Inc. was last trading at $0.57 per share. This represents the most recent stock quote for Century Therapeutics, Inc.. Yesterday, Century Therapeutics, Inc. closed at $0.53 per share.
-
How To Buy Century Therapeutics, Inc. Stock Online?
In order to purchase Century Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IPSC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IPSC
Sector
P/E ratio
--
23.75x
PEG ratio
-0.49x
-0.01x
P/B ratio
0.26x
1.83x
Price / LTM sales
0.40x
1.60x
Growth Metrics
IPSC
Sector
Revenue growth
-100%
4.85%
Earnings growth
-8%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.39
-$0.20
Profitability
IPSC
Sector
Profitability FY 2024
-$6.7M
$3.6M
Return on invested capital
-10.67%
-30.98%
Return on assets
-8.34%
-27.62%
Return on equity
-13.46%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
12
Balance Sheet
IPSC
Sector
Total cash
$132.7M
$27.2M
Short term investments
$130.9M
$25.7M
Total assets
$353.2M
$79.7M
Long term debt
$41.2M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.19% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
